RANI Rani Therapeutics Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RANI

Price (delayed)

$0.8942

Market cap

$110.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.29

Enterprise value

$105.07M

?
Relative Growth: Rel. Growth: 72
Relative Strength: Rel. Strength: 50
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 28
Highlights
RANI's gross profit has surged by 164% year-on-year and by 94% since the previous quarter
The revenue has soared by 164% YoY and by 94% from the previous quarter
The quick ratio has declined by 20% since the previous quarter
The company's equity fell by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RANI

RANI stock price

How has the Rani Therapeutics Holdings stock price performed over time
Intraday
2.18%
1 week
-6.02%
1 month
-4.08%
1 year
59.71%
YTD
-33.76%
QTD
21.69%

Financial performance

How have Rani Therapeutics Holdings's revenue and profit performed over time
Revenue
$3.17M
Gross profit
$3.17M
Operating income
-$34.64M
Net income
-$29.44M
Gross margin
100%
Net margin
-929.1%
RANI's gross profit has surged by 164% year-on-year and by 94% since the previous quarter
The revenue has soared by 164% YoY and by 94% from the previous quarter
The operating margin has surged by 74% year-on-year and by 53% since the previous quarter
The net margin has surged by 63% year-on-year and by 49% since the previous quarter

Price vs fundamentals

How does RANI's price correlate with its fundamentals

Growth

What is Rani Therapeutics Holdings's growth rate over time

Valuation

What is Rani Therapeutics Holdings stock price valuation
P/E
N/A
P/B
3.89
P/S
50.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
33.16
The EPS has soared by 71% YoY and by 36% from the previous quarter
RANI's P/B is 79% below its 5-year quarterly average of 17.8
The company's equity fell by 14% QoQ
The revenue has soared by 164% YoY and by 94% from the previous quarter
RANI's P/S is 51% above its last 4 quarters average of 32.9

Efficiency

How efficient is Rani Therapeutics Holdings business performance
RANI's ROIC has plunged by 148% YoY but it is up by 15% from the previous quarter
Rani Therapeutics Holdings's return on equity has surged by 90% YoY and by 66% QoQ
The ROS has soared by 59% YoY and by 47% from the previous quarter
The ROA has grown by 21% from the previous quarter but it has contracted by 6% YoY

Dividends

What is RANI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RANI.

Financial health

How did Rani Therapeutics Holdings financials performed over time
Rani Therapeutics Holdings's total assets has soared by 115% YoY but it has decreased by 12% from the previous quarter
The total liabilities has declined by 45% year-on-year and by 4.5% since the previous quarter
The debt is 86% smaller than the equity
The company's debt to equity has surged by 102% YoY and by 8% QoQ
The debt has dropped by 85% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.